Expertise in
37
conditions

Dr. Joseph F. Merola

Dermatology | Rheumatology
University Of Texas Southwestern Medical Center At Dallas
5939 Harry Hines Blvd, 
Dallas, TX 
Expertise in
37
conditions
University Of Texas Southwestern Medical Center At Dallas
5939 Harry Hines Blvd, 
Dallas, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Joseph Merola is a Dermatologist and a Rheumatologist in Dallas, Texas. Dr. Merola is highly rated in 37 conditions, according to our data. His top areas of expertise are Psoriasis, Cutaneous Lupus Erythematosus (CLE), Psoriatic Arthritis, and Arthritis.

His clinical research consists of co-authoring 393 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Dermatology
Rheumatology
Licenses
Dermatology in MA
Hospital Affiliations
UT Of Texas Southwestern University Hospital - William P. Clements Jr.
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Baylor Scott & White Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Capital District Physicians Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Cook Children's Health Plan
  • MANAGED MEDICAID PLAN
EMI Health
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Martin's Point Generations
  • MEDICARE MAPD
  • OTHER MEDICARE
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 18 Less Insurance Carriers -

Locations

UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER AT DALLAS
5939 Harry Hines Blvd, Dallas, TX 75235

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: August 03, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects With Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects With Active Cutaneous Lupus Erythematosus With or Without Systemic Manifestations
A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects With Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects With Active Cutaneous Lupus Erythematosus With or Without Systemic Manifestations
Enrollment Status: Completed
Publish Date: November 07, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Terminated
Publish Date: November 08, 2022
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 09, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
Pro-Resolving Mediators in Acute Inflammation in Humans
Pro-Resolving Mediators in Acute Inflammation in Humans
Enrollment Status: Completed
Publish Date: May 26, 2022
Intervention Type: Other, Drug
Study Drug: Lovaza
Study Phase: Early Phase 1
Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis, Dupilumab Study
Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis, Dupilumab Study
Enrollment Status: Terminated
Publish Date: October 04, 2021
Intervention Type: Drug
Study Phase: Phase 4
View 6 Less Clinical Trials

393 Total Publications

Comparative Risk of Infection and Prevalence of Combination Targeted Therapy in Psoriatic Arthritis.
Comparative Risk of Infection and Prevalence of Combination Targeted Therapy in Psoriatic Arthritis.
Journal: JAMA dermatology
Published: August 20, 2025
Similar Doctors
Expertise in
31
conditions
Dr. Melissa M. Mauskar
Dermatology
Expertise in
31
conditions
Dr. Melissa M. Mauskar
Dermatology

University Of Texas Southwestern Medical Center At Dallas

5939 Harry Hines Blvd, 
Dallas, TX 
 (0.1 miles away)
214-645-0624
Languages Spoken:
English
See accepted insurances

Melissa Mauskar is a Dermatologist in Dallas, Texas. Dr. Mauskar is highly rated in 31 conditions, according to our data. Her top areas of expertise are Lichen Sclerosus, Erythema Multiforme, Lichen Planus, and Stevens-Johnson Syndrome.

Expertise in
11
conditions
Dr. Heidi T. Jacobe
Dermatology
Expertise in
11
conditions
Dr. Heidi T. Jacobe
Dermatology

University Of Texas Southwestern Medical Center At Dallas

5939 Harry Hines Blvd, Fl 9, 
Dallas, TX 
 (0.1 miles away)
214-645-6616
Languages Spoken:
English
See accepted insurances

Heidi Jacobe is a Dermatologist in Dallas, Texas. Dr. Jacobe is highly rated in 11 conditions, according to our data. Her top areas of expertise are Localized Scleroderma, Scleroderma, Systemic Sclerosis (SSc), and Scleroma.

Expertise in
27
conditions
Dr. Benjamin F. Chong
Dermatology
Expertise in
27
conditions
Dr. Benjamin F. Chong
Dermatology

University Of Texas Southwestern Medical Center At Dallas

5939 Harry Hines Blvd, Fl 9, 
Dallas, TX 
 (0.1 miles away)
214-645-6616
Languages Spoken:
English
See accepted insurances

Benjamin Chong is a Dermatologist in Dallas, Texas. Dr. Chong is highly rated in 27 conditions, according to our data. His top areas of expertise are Cutaneous Lupus Erythematosus (CLE), Discoid Lupus Erythematosus (DLE), Systemic Lupus Erythematosus (SLE), and Dermatomyositis.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Merola's expertise for a condition
ConditionClose
View All 11 Elite Conditions
View All 22 Advanced Conditions
View All 125 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile